AVXL

Anavex Life Sciences Corp. (AVXL) Management Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Capital Allocation

The company maintains a very strong liquidity position with a current ratio of 18.24x and cash ratio of 18.05x, which supports operational flexibility.

There is no debt burden reflected in the latest ratios, and net current asset value remains positive at 121.7M.

However, profitability and cash generation remain negative, with free cash flow of -34.1M and operating cash flow per share of -0.37, limiting capital allocation optionality.

Execution Operating Discipline

Operating performance remains weak, with negative ROA of -26.5%, ROE of -31.4%, and ROIC of -31.7%.

Income quality is still reasonable at 0.85, suggesting reported results are not heavily distorted by accounting noise.

The business continues to show no meaningful margin support in the latest data, with profitability ratios effectively at zero or negative.

Balance Sheet Stewardship

The balance sheet remains a relative strength, anchored by 18.24x current ratio and 18.05x cash ratio.

Book value per share of 1.31 and tangible book value per share of 1.31 indicate a solid asset base relative to the current share price.

That said, the company is still unprofitable and the solvency ratio is negative, so stewardship quality is constrained by ongoing losses.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Anavex Life Sciences Corp.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →